Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
5. September 2025
3 min to read

Hyperacute T Waves Are Specific for Occlusion Myocardial Infarction, Even Without Diagnostic St Elevation

Overview


This study aimed to derive and validate a quantitative definition of hyperacute T waves (HATW) by developing the HATW score and evaluating its diagnostic accuracy for identifying acute coronary occlusion in patients with possible ACS but without STEMI criteria.

Published in: The Journal of the American College of Cardiology
Published on: 31 August 2025

Background

Despite no objective definition, hyperacute T waves (HATW) are recommended by the American College of Cardiology as a STEMI equivalent finding, requiring emergent reperfusion.

Methods

We retrospectively evaluated adults with possible ACS across five PCI centers. Exclusions were: lack of pre-angiogram ECG, QRS duration ≥110 ms, and elevated troponin without angiogram. The outcome definition was: myocardial infarction with TIMI 0-1 flow culprit lesion. ECG measures included T wave magnitude (T wave area relative to QRS amplitude) and symmetry (T wave peak-to-end time relative to onset-to-peak time). The HATW score was derived and evaluated on separate groups. The primary analysis was HATW score performance for acute coronary occlusion in patients without STEMI criteria.

Results

3,274 patients were reviewed, and 618 were excluded. 1,261 and 1,395 patients were allocated to derivation and validation groups. In derivation the optimal HATW score threshold for ≥ 98% specificity was: 2 consecutive leads with mean HATW score ≥ 0.7. In validation the performance for acute coronary occlusion in the subset without STEMI criteria (N = 1300) was: 98.4% specificity, 20.7% sensitivity, 47.4% PPV, 12.54 LR+. Among patients without STEMI criteria but positive HATW score, 84% had a culprit lesion causing AMI.

Conclusion

The HATW score is the first objective definition of hyperacute T waves showing significant clinical utility as an ECG finding of acute coronary occlusion in potential ACS patients.

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Electrocardiographic Diagnostic Possibilities for Atrial Fibrillation Using Artificial Intelligence: Differentiation from Sinus Rhythm and Other Arrhythmias with the Pmcardio App in Covid-19 Patients

This study evaluated how effectively artificial intelligence can detect atrial fibrillation (AF) in COVID-19 patients using ECG analysis. Researchers compared the PMcardio AI application’s performance with that of cardiologists and infectious disease specialists. Among 116 hospitalized COVID-19 patients, PMcardio achieved perfect diagnostic accuracy (sensitivity and specificity of 1.00) for AF detection, matching cardiologists and surpassing infectious disease specialists. The AI’s performance remained consistent across confidence levels, and its severity assessments correlated significantly with rhythm findings. These results highlight AI’s potential to improve arrhythmia detection, streamline care, and reduce unnecessary in-person evaluations during infectious disease outbreaks.

Door-to-balloon Time Outperforms St-segment Elevation in Predicting the Stemi vs. Nstemi Final Diagnosis

In a two-center registry study, investigators compared traditional STEMI/NSTEMI classification with angiographic and interventional diagnoses. Although guideline-defined ST-elevation criteria underpin quality metrics and reperfusion standards, they often fail to capture acute coronary occlusion myocardial infarction (OMI). This discordance has led to proposals for an OMI/Non-OMI paradigm, grounded in pathophysiology rather than ECG morphology. The study examined whether door-to-balloon time < 120 min aligns more closely with final cardiologist adjudication than either ST-segment elevation on ECG or angiographic evidence of TIMI 0–1 flow.

Join over 100,000 healthcare professionals who are already taking advantage of AI